Overview

Clients rely on James J. Rodgers for seasoned judgment and strategic clarity in complex antitrust and commercial litigation. Jim is known for helping clients navigate high-stakes disputes with perspective gained from decades of trial, appellate, and leadership experience.

James J. Rodgers is a partner at Dilworth Paxson LLP and chair of the firm’s Antitrust Practice Group. For decades, Jim has litigated complex commercial cases at both the trial and appellate levels across the country, including matters involving antitrust, intellectual property, contract disputes, fraud claims, class actions and bankruptcy issues. Clients and colleagues count on him for strategic discipline, careful analysis and the ability to see how individual decisions affect the trajectory of a case. His experience representing Fortune 500 companies, private businesses, public entities and individuals allows him to approach disputes with both legal depth and practical perspective.

Over the course of his career, Jim has tried cases in federal and state courts nationwide and handled appeals in significant antitrust and intellectual property matters. He is particularly attentive to building cases with an eye toward appellate review, ensuring that arguments are framed effectively from the outset. Clients often turn to him when disputes involve complicated legal frameworks or require coordination across multiple jurisdictions. In addition to his litigation practice, Jim served for many years as chair of the firm’s Ethics Committee, advising lawyers within the firm and representing attorneys in disciplinary matters, experience that reinforces his thoughtful and principled approach to advocacy.

Jim approaches complex disputes with the perspective of someone who has seen matters evolve through every stage of litigation. He believes that careful preparation, intellectual rigor and mentorship within litigation teams ultimately benefit clients. As chair of the Antitrust Practice Group and as an adjunct professor teaching antitrust law, he invests in developing the next generation of lawyers while guiding teams through sophisticated matters. When clients face uncertainty, they often seek his counsel not only on the strength of their claims, but on how best to position the case for long-term success. Jim helps them move forward with clear strategy, disciplined advocacy and the benefit of decades of experience. He has also maintained a longstanding commitment to community leadership, including service as president of the Board of the Philadelphia Children’s Foundation and as president of Crescent Boat Club of Philadelphia, where he represented the club as a delegate to the Board of the Schuylkill Navy.

Representative Experience

  • Represents Franklin Organic Mushrooms, Inc., as a defendant in antitrust litigation in the Eastern District of Pennsylvania and represents Maxrelief USA, Inc. in Lanham Act litigation in the Eastern District of Pennsylvania.
  • Concluded representation of TCC Communications, Inc. in contract litigation in the Eastern District of New York.
  • Represented the former corporate counsel of a nonprofit entity in an action under the Pennsylvania Whistleblower Law alleging termination in retaliation for complaints regarding alleged misconduct by officers and directors. The Pennsylvania Attorney General subsequently pursued the same defendants.
  • Served as co-counsel for Mutual Pharmaceutical Co., Inc. in In re: Skelaxin (Metaxalone) Antitrust Litigation, MDL 2343 (E.D. Tenn.), and in SigmaPharm, Inc. v. King Pharmaceuticals, Inc., 772 F. Supp. 2d 660 (E.D. Pa. 2011), aff’d (3d Cir. 2012), petition for certiorari denied, as well as in SB Pharmco Puerto Rico v. United Research Laboratories, Inc., 552 F. Supp. 2d 500 (E.D. Pa. 2008), (Patent and Antitrust)
  • Served as lead counsel for two patent infringement defendants in Pharmastem Therapeutics, Inc. v. ViaCell, Inc., 491 F.3d 1342 (Fed. Cir. 2007), certiorari denied, 552 U.S. 1255 (2008), and in related multidistrict litigation, In re: Pharmastem Therapeutics, Inc. Patent Litigation, MDL 1660 (D. Del.).

Professional & Community Activities

  • Primary outside counsel to the Urban Affairs Coalition of Philadelphia
  • Leader, Fordham University Club of the Delaware Valley, 1999 – present
  • Vice President of the Fordham College Alumni Association, 2006 – 2010
  • Chair, Philadelphia Bar Association, Antitrust Committee, 1996 – 1998
  • President, Crescent Boat Club of Philadelphia, 2021-present

Speeches & Presentations

  • Co-presenter, Ethical Issues in Mergers and Acquisitions: Problems Facing In-House Counsel, DELVACCA’s Corporate and Securities CLE Institute, Philadelphia, PA, September 4, 2014.

Professional Recognition

  • Selected to The Best Lawyers in America® in the area of Litigation – Antitrust, 2008- Present
  • Appeared in the 2006-09 editions of Chambers USA – America’s Leading Lawyers for Business, as a Leader in his field
  • Chair, Antitrust Committee of the Philadelphia Bar Association, 1996-98
  • Lecturer, Continuing Legal Education programs, Pennsylvania Bar Institute, and Philadelphia Bar Association
  • Pennsylvania Super Lawyers, 2005-Present

 

Further information on methodologies is available via these links.

Representative Experience

  • Represents Franklin Organic Mushrooms, Inc., as a defendant in antitrust litigation in the Eastern District of Pennsylvania and represents Maxrelief USA, Inc. in Lanham Act litigation in the Eastern District of Pennsylvania.
  • Concluded representation of TCC Communications, Inc. in contract litigation in the Eastern District of New York.
  • Represented the former corporate counsel of a nonprofit entity in an action under the Pennsylvania Whistleblower Law alleging termination in retaliation for complaints regarding alleged misconduct by officers and directors. The Pennsylvania Attorney General subsequently pursued the same defendants.
  • Served as co-counsel for Mutual Pharmaceutical Co., Inc. in In re: Skelaxin (Metaxalone) Antitrust Litigation, MDL 2343 (E.D. Tenn.), and in SigmaPharm, Inc. v. King Pharmaceuticals, Inc., 772 F. Supp. 2d 660 (E.D. Pa. 2011), aff’d (3d Cir. 2012), petition for certiorari denied, as well as in SB Pharmco Puerto Rico v. United Research Laboratories, Inc., 552 F. Supp. 2d 500 (E.D. Pa. 2008), (Patent and Antitrust)
  • Served as lead counsel for two patent infringement defendants in Pharmastem Therapeutics, Inc. v. ViaCell, Inc., 491 F.3d 1342 (Fed. Cir. 2007), certiorari denied, 552 U.S. 1255 (2008), and in related multidistrict litigation, In re: Pharmastem Therapeutics, Inc. Patent Litigation, MDL 1660 (D. Del.).

Insights